BGI Genomics Co Ltd (300676) - Total Assets
Based on the latest financial reports, BGI Genomics Co Ltd (300676) holds total assets worth CN¥11.35 Billion CNY (≈ $1.66 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300676 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
BGI Genomics Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's total assets have evolved over time, based on quarterly financial data. See BGI Genomics Co Ltd book value and equity for net asset value and shareholders' equity analysis.
BGI Genomics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
BGI Genomics Co Ltd's total assets of CN¥11.35 Billion consist of 52.3% current assets and 47.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 28.0% |
| Accounts Receivable | CN¥1.65 Billion | 14.1% |
| Inventory | CN¥480.20 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥468.94 Million | 4.0% |
| Goodwill | CN¥36.47 Million | 0.3% |
Asset Composition Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of BGI Genomics Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BGI Genomics Co Ltd's current assets represent 52.3% of total assets in 2025, a decrease from 81.0% in 2012.
- Cash Position: Cash and equivalents constituted 28.0% of total assets in 2025, down from 35.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
BGI Genomics Co Ltd Competitors by Total Assets
Key competitors of BGI Genomics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
BGI Genomics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.60 | 2.85 | 3.46 |
| Quick Ratio | 2.39 | 2.62 | 3.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.57 Billion | CN¥4.47 Billion | CN¥7.67 Billion |
BGI Genomics Co Ltd - Advanced Valuation Insights
This section examines the relationship between BGI Genomics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | CN¥11.75 Billion |
| Market Capitalization | $2.25 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BGI Genomics Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BGI Genomics Co Ltd's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual total assets of BGI Genomics Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥11.75 Billion ≈ $1.72 Billion |
-6.32% |
| 2024-12-31 | CN¥12.54 Billion ≈ $1.84 Billion |
-7.87% |
| 2023-12-31 | CN¥13.61 Billion ≈ $1.99 Billion |
-5.37% |
| 2022-12-31 | CN¥14.39 Billion ≈ $2.10 Billion |
+0.92% |
| 2021-12-31 | CN¥14.25 Billion ≈ $2.09 Billion |
+25.59% |
| 2020-12-31 | CN¥11.35 Billion ≈ $1.66 Billion |
+89.96% |
| 2019-12-31 | CN¥5.97 Billion ≈ $874.29 Million |
+16.37% |
| 2018-12-31 | CN¥5.13 Billion ≈ $751.29 Million |
+0.44% |
| 2017-12-31 | CN¥5.11 Billion ≈ $748.02 Million |
+20.84% |
| 2016-12-31 | CN¥4.23 Billion ≈ $619.00 Million |
+8.16% |
| 2015-12-31 | CN¥3.91 Billion ≈ $572.28 Million |
+90.88% |
| 2014-12-31 | CN¥2.05 Billion ≈ $299.82 Million |
+36.83% |
| 2013-12-31 | CN¥1.50 Billion ≈ $219.12 Million |
+49.19% |
| 2012-12-31 | CN¥1.00 Billion ≈ $146.87 Million |
-- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more